Research Products & Services
RiboMed provides a variety of versitle bisulfite-free research tools and services for the study of CpG methlation in DNA.
• MethylMeter®: Quantitative DNA Methylation Detection
• MethylMagnet®: Ultra Sensitive Methylated DNA isolation
• CAP: Pioneering ”Coupled Abscription PCR ” DNA Methylation Detection
Clinical Diagnostics
RiboMed’s proprietary Abscription®-based DNA methylation diagnostic tests are leading the way in epigenetic and cancer diagnostics.
• Proprietary bisulfite free DNA Methylation Detection Clinical Diagnostic Assay Platform
• Prognostic Brain Tumor FFPE Assay Now Available Through Castle Biosciences
• Theranostic Ovarian Cancer Assay (Q4 2012)
Latest News
• April 2012 – RiboMed Launches Prognostic Test for Glioma Brain Cancer
RiboMed Receives Notice of Allowance for Three New Patents (a) Detecting CpG Methylation With a Methyl CpG Binding Protein (b) Molecular Beacon Abscription Detection (c) Abscription-Based Molecular Detection



